Literature DB >> 4082913

Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis.

M Iivanainen, R Laaksonen, M L Niemi, M Färkkilä, L Bergström, K Mattson, A Niiranen, K Cantell.   

Abstract

Patients with amyotrophic lateral sclerosis were treated with high-dose intravenous infusion of human leukocyte interferon for six days. Neuropsychological examinations were carried out before, during and after the treatment. Marked reversible dysfunction was detected in immediate memory functions, coordination of hand movements, and drawing. Motor perseveration, micrographia, and slowing of behaviour were also observed. Changes appeared four to 12 days after start of treatment, with the peak on days six to eight. Recovery was almost complete by day 15. Intellectual ability, as measured by three WAIS subtests, praxis of hand movements, visuognostic functions, speech, reading, writing, and calculation remained essentially unaffected. The profile of the neuropsychological deficits observed, the absence of defects typical of focal posterior cortical lesions, the simultaneously slowed electroencephalographic activity with frontal accentuation, and the increased central conduction times of brain stem auditory evoked potentials suggest frontobasal involvement.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4082913     DOI: 10.1111/j.1600-0404.1985.tb00904.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  8 in total

1.  Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities.

Authors:  F Adams; F Fernandez; G Mavligit
Journal:  J Neurooncol       Date:  1988-12       Impact factor: 4.130

Review 2.  Neuropsychiatric adverse effects of interferon-alpha: recognition and management.

Authors:  Charles L Raison; Marina Demetrashvili; Lucile Capuron; Andrew H Miller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  Interferons, signal transduction pathways, and the central nervous system.

Authors:  Shreeram C Nallar; Dhan V Kalvakolanu
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

Review 4.  Clinical toxicity of the interferons.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

Review 5.  Neuropsychiatric disorders related to interferon and interleukins treatment.

Authors:  Aye Mu Myint; Markus J Schwarz; Harry W M Steinbusch; Brian E Leonard
Journal:  Metab Brain Dis       Date:  2008-12-10       Impact factor: 3.584

6.  Micrographia and related deficits in Parkinson's disease: a cross-sectional study.

Authors:  Aparna Wagle Shukla; Songthip Ounpraseuth; Michael S Okun; Vickie Gray; John Schwankhaus; Walter Steven Metzer
Journal:  BMJ Open       Date:  2012-06-25       Impact factor: 2.692

7.  Behavioral effects of upper respiratory tract illnesses: a consideration of possible underlying cognitive mechanisms.

Authors:  Andrew P Smith
Journal:  Behav Sci (Basel)       Date:  2012-03-15

8.  Aberrant Auditory Steady-State Response of Awake Mice Induced by Chronic Interferon-α Treatment.

Authors:  Yingzhuo Li; Xuejiao Wang; Jingyu Chen; Zijie Li; Pingting Yang; Ling Qin
Journal:  Front Pharmacol       Date:  2021-01-27       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.